Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19198946 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | May 2025 | January 2026 | Allow | 8 | 2 | 0 | No | No |
| 19194986 | IMMUNOTHERAPEUTIC COMPOSITION FOR PREVENTION OF OBESITY, NONALCOHOLIC FATTY LIVER DISEASE AND HYPERTRIGLYCERIDEMIA, AND METHODS OF USE AND PREPARATION THEREOF | April 2025 | October 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 19061157 | METHODS OF TREATING INFLAMMATORY AND/OR ALLERGIC DISORDERS WITH NORKETOTIFEN | February 2025 | December 2025 | Abandon | 9 | 1 | 1 | No | No |
| 19048808 | Production of Biosimilar Ustekinumab In CHO Cells | February 2025 | March 2026 | Allow | 13 | 2 | 1 | Yes | No |
| 18774646 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | July 2024 | April 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18774629 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | July 2024 | March 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18774608 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | July 2024 | January 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18764499 | ENHANCED PEPTIDE CONSTRUCTS FOR ALBUMIN BINDING | July 2024 | May 2025 | Abandon | 10 | 1 | 1 | Yes | No |
| 18444471 | COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF AMYLIN ANALOGS AND USES THEREOF | February 2024 | November 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18439344 | Nano-sized Chitosan/VS2 nanocomposite like flowers for Antimicrobial Applications | February 2024 | November 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18439336 | Method for Making Nano-sized Chitosan/VS2 Nanocomposites | February 2024 | October 2024 | Allow | 8 | 2 | 0 | No | No |
| 18507324 | Nano-sized Chitosan/VS2 nanocomposite like flowers for Potential Pharmaceutical Applications | November 2023 | July 2024 | Allow | 9 | 2 | 1 | Yes | No |
| 18341437 | COMPOSITIONS AND METHODS FOR TREATING SYNUCLEINOPATHIES | June 2023 | May 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18324097 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | May 2023 | March 2024 | Allow | 10 | 2 | 1 | No | No |
| 18305919 | Production of Biosimilar Ustekinumab in CHO Cells | April 2023 | June 2024 | Allow | 13 | 2 | 0 | Yes | No |
| 18300064 | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE | April 2023 | January 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18117995 | COMPOSITIONS COMPRISING PEPTIDES THAT BLOCK TRANSMISSION OF ORTHOTOSPOVIRUSES | March 2023 | July 2025 | Allow | 28 | 1 | 1 | No | No |
| 18105772 | Stabilized Formulations Containing Anti-IL-33 Antibodies | February 2023 | January 2026 | Allow | 35 | 2 | 0 | No | No |
| 18162791 | STABLE ANTIBODY FORMULATION | February 2023 | December 2025 | Allow | 35 | 1 | 0 | No | No |
| 18161036 | PROTEIN-TYPE NANOPARTICLES, PREPARATION METHODS, AND APPLICATION THEREOF | January 2023 | December 2023 | Allow | 11 | 2 | 1 | No | No |
| 18086031 | HIGH CONCENTRATION ANTI-C5 ANTIBODY FORMULATIONS | December 2022 | February 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18002248 | COMBINING IPSC DERIVED EFFECTOR CELL TYPES FOR IMMUNOTHERAPY USE | December 2022 | December 2024 | Allow | 24 | 2 | 1 | Yes | Yes |
| 17926313 | ANTIBODY-CONTAINING FORMULATION | November 2022 | October 2025 | Allow | 35 | 3 | 1 | Yes | No |
| 18054101 | COMPOSITIONS AND METHODS FOR ENHANCING TRIPLEX AND NUCLEASE-BASED GENE EDITING | November 2022 | November 2024 | Abandon | 24 | 2 | 1 | No | No |
| 17959272 | Modified Clostridial Neurotoxins as Vaccine and Conjugate Vaccine Platforms | October 2022 | December 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17913457 | ANTIBODIES | September 2022 | March 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17911167 | PHARMACEUTICAL LIQUID COMPOSITION HAVING INCREASED STABILITY | September 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17890866 | PHARMACEUTICAL FORMULATIONS OF TNF-ALPHA ANTIBODIES | August 2022 | July 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17864622 | Immunoglobulin Preparation and Storage System for an Immunoglobulin Preparation | July 2022 | October 2025 | Allow | 39 | 2 | 0 | Yes | No |
| 17863587 | METHOD FOR PURIFYING IMMUNOGLOBULIN SOLUTIONS | July 2022 | June 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17808029 | ANTIBODY FORMULATIONS | June 2022 | July 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17786251 | IGG:TGFBETARII FUSION PROTEIN COMPOSITION | June 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17831645 | EXCIPIENT COMPOUNDS FOR PROTEIN PROCESSING | June 2022 | June 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17832463 | METHODS AND FORMULATIONS FOR REDUCING RECONSTITUTION TIME OF LYOPHILIZED POLYPEPTIDES | June 2022 | June 2025 | Allow | 36 | 2 | 0 | Yes | No |
| 17738870 | ROOM TEMPERATURE STABLE LYOPHILIZED PROTEIN | May 2022 | September 2025 | Allow | 40 | 2 | 1 | No | No |
| 17773538 | METHODS, COMPOSITIONS, AND VACCINES FOR TREATING A VIRUS INFECTION | April 2022 | September 2025 | Abandon | 41 | 3 | 1 | No | Yes |
| 17732224 | Thermostable Vaccine Compositions and Methods of Preparing The Same | April 2022 | June 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17731718 | FORMULATION CONTAINING TLR AGONIST AND METHODS OF USE | April 2022 | July 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17731671 | FORMULATION CONTAINING TLR AGONIST AND METHODS OF USE | April 2022 | May 2025 | Allow | 37 | 2 | 1 | Yes | No |
| 17726741 | HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) | April 2022 | March 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17690437 | METHODS PROVIDING A THERAPEUTIC MACROMOLECULE AND SYNTHETIC NANOCARRIERS COMPRISING IMMUNOSUPPRESSANT LOCALLY AND CONCOMITANTLY TO REDUCE BOTH TYPE 1 AND TYPE IV HYPERSENSITIVITY | March 2022 | July 2025 | Allow | 40 | 2 | 0 | No | No |
| 17675488 | USE OF THE IL-1BETA BINDING ANTIBODY CANAKINUMAB FOR TREATING OR ALLEVIATING SYMPTOMS OF PULMONARY SARCOIDOSIS | February 2022 | February 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17673149 | PHARMACEUTICAL FORMULATIONS FOR ADALIMUMAB | February 2022 | July 2025 | Allow | 41 | 2 | 0 | Yes | Yes |
| 17584286 | PROTEIN FORMULATIONS AND METHODS OF MAKING SAME | January 2022 | February 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17572350 | Production of Biosimilar Ustekinumab In CHO Cells | January 2022 | March 2025 | Abandon | 38 | 1 | 1 | No | No |
| 17564976 | Methods and Devices for the Enrichment of Immunoglobulin from Blood | December 2021 | March 2026 | Allow | 50 | 4 | 0 | Yes | No |
| 17562480 | CXCR5 ANTIBODY FORMULATIONS | December 2021 | January 2026 | Allow | 49 | 4 | 0 | No | No |
| 17554758 | METHODS FOR ENHANCED REMOVAL OF IMPURITIES DURING PROTEIN A CHROMATOGRAPHY | December 2021 | September 2025 | Allow | 45 | 2 | 1 | No | No |
| 17552392 | METHODS FOR PROVIDING POLYMERIC SYNTHETIC NANOCARRIERS FOR GENERATING ANTIGEN-SPECIFIC TOLERANCE IMMUNE RESPONSES | December 2021 | May 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17542632 | VISCOSITY REDUCTION OF HIGHLY CONCENTRATED PROTEIN FORMULATIONS | December 2021 | December 2024 | Allow | 36 | 2 | 1 | No | No |
| 17457456 | USE OF AMINO ACIDS AS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH CONCENTRATIONS OF PROTEIN-BASED THERAPEUTIC AGENTS | December 2021 | May 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17534218 | NANOENCAPSULATION OF ANTIGEN-BINDING MOLECULES | November 2021 | August 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17455713 | FORMULATIONS OF MONOCLONAL ANTIBODIES | November 2021 | February 2025 | Abandon | 39 | 3 | 0 | No | No |
| 17519141 | HIGH CONCENTRATION IMMUNOGLOBULIN COMPOSITION FOR PHARMACEUTICAL APPLICATION | November 2021 | October 2024 | Allow | 35 | 2 | 1 | No | No |
| 17608546 | PHARMACEUTICAL FORMULATIONS CONTAINING CD80 EXTRACELLULAR DOMAIN-FC FUSION PROTEINS | November 2021 | March 2026 | Allow | 52 | 2 | 1 | Yes | No |
| 17514957 | PROCESS FOR PREPARING AN IMMUNOGLOBULIN PREPARATION | October 2021 | September 2024 | Allow | 34 | 2 | 0 | No | No |
| 17503759 | Novel Formulations Which Stabilize Low Dose Antibody Compositions | October 2021 | April 2025 | Abandon | 41 | 2 | 1 | No | No |
| 17487801 | COMPOSITION COMPRISING CATALASE, PREPARATION METHOD AND USE THEREOF AND METHOD FOR KILLING TUMOR CELLS | September 2021 | September 2025 | Allow | 48 | 4 | 1 | Yes | No |
| 17437634 | PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-LINGO-1 ANTIBODIES | September 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17470270 | METHODS AND COMPOSITIONS FOR TARGETING T-CELL CANCERS | September 2021 | June 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17460979 | IMMUNOGENIC COMPOSITION FOR THE TREATMENT OF CANCER AND METHODS OF PREPARING THE SAME | August 2021 | March 2024 | Allow | 30 | 1 | 0 | No | No |
| 17400880 | CD154 PEPTIDES AND METHODS OF REDUCING INFLAMMATION | August 2021 | February 2026 | Allow | 54 | 2 | 1 | No | No |
| 17393888 | METHODS FOR PREPARING ALUMINUM PRECIPITATE COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES | August 2021 | January 2025 | Allow | 42 | 3 | 1 | Yes | No |
| 17391663 | NANOPARTICLES, CONTROLLED-RELEASE DOSAGE FORMS, AND METHODS FOR DELIVERING AN IMMUNOTHERAPEUTIC AGENT | August 2021 | January 2025 | Abandon | 42 | 2 | 1 | No | No |
| 17387239 | PHOSPHOSERINE CONTAINING COMPOSITIONS FOR IMMUNE TOLERANCE INDUCTION | July 2021 | September 2025 | Abandon | 49 | 2 | 1 | No | Yes |
| 17386385 | COMPOSITIONS AND METHODS FOR STABILIZING PROTEIN-CONTAINING FORMULATIONS | July 2021 | November 2023 | Allow | 28 | 2 | 0 | No | No |
| 17423927 | OIL/SURFACTANT MIXTURES FOR SELF-EMULSIFICATION | July 2021 | September 2025 | Abandon | 50 | 0 | 1 | No | No |
| 17378025 | STABLE LIQUID ANTIBODY FORMULATION | July 2021 | February 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17350781 | LIPOSOME COMPOSITIONS COMPRISING PAM2CYS OR PAM3CYS ADJUVANT AND METHODS FOR INDUCING A HUMORAL IMMUNE RESPONSE | June 2021 | August 2024 | Abandon | 38 | 2 | 0 | No | No |
| 17332521 | EXCIPIENT COMPOUNDS FOR PROTEIN PROCESSING | May 2021 | November 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17328408 | Method for the reduction of host cell proteins in affinity chromatography | May 2021 | July 2025 | Allow | 49 | 2 | 0 | Yes | No |
| 17320693 | STABILIZED ANTIBODY COMPOSITIONS | May 2021 | January 2024 | Allow | 32 | 2 | 0 | No | No |
| 17316585 | Thermostable Vaccine Compositions and Methods of Preparing same | May 2021 | May 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17291956 | METHOD OF IMPROVING BLOOD KINETICS OF PEPTIDE | May 2021 | November 2025 | Allow | 54 | 3 | 1 | Yes | No |
| 17291194 | ANTI-PTK7 IMMUNE CELL CANCER THERAPY | May 2021 | March 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17246288 | METHODS AND COMPOSITIONS FOR INCREASING IDURONATE 2-SULFATASE ACTIVITY IN THE CNS | April 2021 | March 2024 | Allow | 34 | 2 | 0 | Yes | No |
| 17233008 | Composition Comprising an Antibody | April 2021 | July 2024 | Allow | 39 | 2 | 0 | Yes | No |
| 17225887 | Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies | April 2021 | April 2024 | Allow | 36 | 2 | 0 | No | No |
| 17224900 | FORMULATIONS OF MONOCLONAL ANTIBODIES | April 2021 | October 2024 | Abandon | 43 | 2 | 1 | No | No |
| 17282382 | Multimeric Hybrid Fc Proteins for Replacement of IVIG | April 2021 | September 2025 | Allow | 53 | 3 | 1 | Yes | No |
| 17211459 | METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE | March 2021 | January 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17211399 | AQUEOUS PHARMACEUTICAL FORMULATIONS | March 2021 | December 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17208300 | HUMAN iPSC-DERIVED BRAIN ORGANOIDS AND USES THEREOF | March 2021 | August 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17200552 | CONJUGATE VACCINE TARGETING A DISEASE-CAUSING BIOLOGICAL PROTEIN | March 2021 | March 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17197603 | COMPOSITIONS OF IL-6/IL-6R ANTIBODIES AND METHODS OF USE THEREOF | March 2021 | November 2024 | Abandon | 44 | 2 | 1 | No | No |
| 17191589 | IMMUNOGLOBULIN FORMULATION AND METHOD OF PREPARATION THEREOF | March 2021 | September 2024 | Abandon | 43 | 2 | 1 | No | No |
| 17179223 | NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAP | February 2021 | July 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 17177022 | HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS | February 2021 | November 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17175162 | EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS | February 2021 | August 2023 | Allow | 30 | 6 | 1 | Yes | No |
| 17170667 | COMPOSITIONS AND METHODS FOR TREATING POMPE DISEASE | February 2021 | November 2024 | Allow | 45 | 3 | 1 | Yes | No |
| 17165704 | PROTEIN-NANOPARTICLE CONJUGATE PURIFICATION METHODS | February 2021 | October 2023 | Allow | 32 | 2 | 0 | No | No |
| 17155432 | STABLE ANTIBODY FORMULATION | January 2021 | February 2025 | Allow | 49 | 5 | 0 | Yes | No |
| 17154108 | METHODS OF PURIFICATION | January 2021 | August 2025 | Abandon | 55 | 2 | 1 | No | No |
| 17152054 | COMPOSITIONS COMPRISING AN ANTI-C5 ANTIBODY | January 2021 | October 2023 | Abandon | 33 | 2 | 0 | No | No |
| 17260334 | FCRN ANTIBODY COMPOSITIONS | January 2021 | April 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17141690 | CLEAVED HIGH MOLECULE WEIGHT KININOGEN (HMWK) ANTIBODIES AND METHODS OF USING | January 2021 | August 2025 | Allow | 55 | 1 | 2 | Yes | No |
| 17141271 | NOVEL ANTIGEN BINDING DIMER-COMPLEXES, METHODS OF MAKING/AVOIDING AND USES THEREOF | January 2021 | July 2025 | Allow | 55 | 6 | 0 | Yes | No |
| 17254508 | METHODS OF PRODUCING ANTI-C5 ANTIBODIES | December 2020 | April 2025 | Allow | 51 | 2 | 0 | No | No |
| 17128736 | METHOD FOR TREATMENT OF A LEUKOCYTE RELATED DISEASE BY DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES USING TARGETED LIPID PARTICLES | December 2020 | April 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17251122 | MULTI-SPECIFIC ANTIBODY CONSTRUCTS | December 2020 | July 2025 | Allow | 55 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KIM, YUNSOO.
With a 55.6% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 31.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KIM, YUNSOO works in Art Unit 1641 and has examined 206 patent applications in our dataset. With an allowance rate of 78.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 46 months.
Examiner KIM, YUNSOO's allowance rate of 78.2% places them in the 46% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by KIM, YUNSOO receive 3.01 office actions before reaching final disposition. This places the examiner in the 87% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by KIM, YUNSOO is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +38.1% benefit to allowance rate for applications examined by KIM, YUNSOO. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.0% of applications are subsequently allowed. This success rate is in the 30% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 57.8% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 120.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 81% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 76.9% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 56.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 60.5% are granted (fully or in part). This grant rate is in the 65% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 6.3% of allowed cases (in the 88% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.2% of allowed cases (in the 63% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.